These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 25360866)

  • 41. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilar monoclonal antibodies: a science-based regulatory challenge.
    Declerck PJ
    Expert Opin Biol Ther; 2013 Feb; 13(2):153-6. PubMed ID: 23286777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin.
    Reichel C; Thevis M
    Bioanalysis; 2013 Mar; 5(5):587-602. PubMed ID: 23425274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The story of biosimilars--chance or threat?].
    Woroń J; Kocić I
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Biosimilar medicines].
    Gjersvik P; Madsen S
    Tidsskr Nor Laegeforen; 2015 Jun; 135(10):962. PubMed ID: 26037760
    [No Abstract]   [Full Text] [Related]  

  • 46. The rise of the biosimilar.
    McCamish M; Woollett G
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):597-9. PubMed ID: 23234317
    [No Abstract]   [Full Text] [Related]  

  • 47. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
    Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
    Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comments on the FDA draft guidance on biosimilar products.
    Chow SC; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):364-9. PubMed ID: 22903309
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Appropriate selection of biochemical targets is one of the most important driver of cost-effectiveness in the discovery of new medicines. Preface.
    Lawton G; Witty DR
    Prog Med Chem; 2008; 46():v-vi. PubMed ID: 18381122
    [No Abstract]   [Full Text] [Related]  

  • 50. First biosimilar drug set to enter US market.
    Ledford H
    Nature; 2015 Jan; 517(7534):253-4. PubMed ID: 25592512
    [No Abstract]   [Full Text] [Related]  

  • 51. [Experiences with price competition of biosimilar drugs in Hungary].
    Hornyák L; Nagy Z; Tálos Z; Endrei D; Ágoston I; Csákvári T; Boncz I
    Acta Pharm Hung; 2014; 84(2):83-7. PubMed ID: 25167704
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Biosimilars--opportunity or threat?].
    Swierkot J
    Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF.
    Salesi N; Di Cocco B; Colonna M; Veltri E
    Future Oncol; 2012 May; 8(5):625-30. PubMed ID: 22401144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Biosimilars: assessment of efficacy, safety and cost].
    Domínguez-Gil Hurlé A
    Farm Hosp; 2010 Mar; 34 Suppl 1():25-8. PubMed ID: 20920855
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biosimilars: impact of differences with Hatch-Waxman.
    Kowalchyk K; Crowley-Weber C
    Pharm Pat Anal; 2013 Jan; 2(1):29-37. PubMed ID: 24236968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The science of biosimilars.
    Bourzac K
    Cancer Discov; 2012 Apr; 2(4):295. PubMed ID: 22576194
    [No Abstract]   [Full Text] [Related]  

  • 60. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.